Drugs targeting the renin-angiotensin-aldosterone system (RAAS) including angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), β-adrenergic receptor blockers, and mineralocorticoid receptor antagonists (MRAs) have been shown to ameliorate the symptoms of HF and improve outcomes including HF re-admissions and mortality [10,35]. Here, ACE is linked to hydrops fetalis.